Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons  by Wang, Jia et al.
Biochimica et Biophysica Acta 1832 (2013) 618–625
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isPro-inﬂammatory cytokines modulate iron regulatory protein 1
expression and iron transportation through reactive oxygen/nitrogen
species production in ventral mesencephalic neuronsJia Wang 1, Ning Song 1, Hong Jiang, Jun Wang, Junxia Xie ⁎
Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders and State Key Disciplines: Physiology,
Medical College of Qingdao University, Qingdao 266071, ChinaAbbreviations: DMT1, divalent metal transporter 1;
iNOS, inducible NO synthetase; IL-1β, interleukin-1β;
regulatory protein; IRE, iron responsive element; LP
1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phen
NAC, N-acetyl-L-cysteine; NO, nitric oxide; L-NAME, Nω
hydrochloride; PD, Parkinson's disease; ROS, reactive o
nigra; TfR1, transferrin receptor 1; TNF-α, tumor necro
droxylase; VM, ventral mesencephalon
⁎ Corresponding author. Tel.: +86 532 85955891; fax
E-mail address: jxiaxie@public.qd.sd.cn (J. Xie).
1 These authors contributed equally to this work.
0925-4439/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbadis.2013.01.021a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 August 2012
Received in revised form 11 December 2012
Accepted 24 January 2013
Available online 31 January 2013
Keywords:
Interleukin-1β
Tumor necrosis factor-α
Iron
Iron regulatory protein 1
Microglia
NeuronBoth inﬂammatory processes associated with microglia activation and abnormal iron deposit in dopaminergic
neurons are involved in the pathogenesis of Parkinson's disease (PD). However, the relationship between
neuroinﬂammation and iron accumulationwas not fully elucidated. In the present study,we aimed to investigate
whether the pro-inﬂammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) released
by microglia, could affect cellular iron transportation in primary cultured ventral mesencephalic (VM) neurons.
The results showed that IL-1β or TNF-α treatment led to increased ferrous iron inﬂux and decreased iron efﬂux in
these cells, due to the upregulation of divalentmetal transporter 1with the iron response element (DMT1+IRE)
and downregulation of ferroportin1 (FPN1). Increased levels of iron regulatory protein 1 (IRP1), transferrin
receptor 1 (TfR1) and hepcidin were also observed in IL-1β or TNF-α treated VM neurons. IRP1 upregulation
could be fully abolished by co-administration of radical scavenger N-acetyl-L-cysteine and inducible NO synthe-
tase inhibitorNω-nitro-L-argininemethyl ester hydrochloride. Further experiments demonstrated that IL-1β and
TNF-α release was remarkably enhanced by iron load in activated microglia triggered by lipopolysaccharide or
1-methyl-4-phenylpyridinium (MPP+). In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated
mice, salicylate application could not block DMT1+IRE upregulation in dopaminergic neurons of substantia
nigra. These results suggested that IL-1β and TNF-α released by microglia, especially under the condition of
iron load, might contribute to iron accumulation in VM neurons by upregulating IRP1 and hepcidin levels
through reactive oxygen/nitrogen species production. This might provide a new insight into unraveling that
microglia might aggravate this iron mediated neuropathologies in PD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is an age-related neurodegenerative disor-
der characterized by selective loss of dopaminergic neurons in the
substantia nigra (SN) pars compacta and consequently leading to dopa-
mine (DA) depletion in the striatum. Increasing evidence suggests that
neuro-inﬂammation, characterized by microglia activation and secre-
tion of pro-inﬂammatory cytokines, is an active process in PD. Elevated
cytokines interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α)FAC, ferric ammonium citrate;
FPN1, ferroportin 1; IRP, iron
S, lipopolysaccharide; MPP+,
yl-1,2,3,6-tetrahydropyridine;
-nitro-L-arginine methyl ester
xygen species; SN, substantia
sis factor-α; TH, tyrosine hy-
: +86 532 83780136.
l rights reserved.were detected in the SN and striatum of PD patients and animal models
[1,2]. Direct intra-parenchymal injection of TNF-α or IL-1β induced
dopaminergic neuron degeneration [3], and speciﬁc inhibition of
IL-1β or TNF-α attenuate the death of dopaminergic neurons in
6-hydroxydopamine (6-OHDA) or lipopolysaccharide (LPS) induced
PD models [4,5]. The two pro-inﬂammatory cytokines may not only
associate with PD pathogenesis by themselves, but actually aggra-
vate PD evolvement [6]. However, the mechanisms underlying ele-
vated cytokines induced neurotoxicity are not fully elucidated.
Levels of total iron and ferric iron were ﬁrst reported to respec-
tively increase by 176% and 225% in the SNpc of PD patients relative
to age-matched controls [7].Compelling evidence exists that nigral
abnormal iron metabolism, is one of the initial events that contrib-
ute to dopaminergic neuron degeneration in PD [8–10]. Especially
in single dopaminergic neurons, iron levels are elevated in PD pa-
tients [11]. Identiﬁcation of several iron transporters has expanded
our knowledge of transmembrane iron trafﬁc and disrupted intracellu-
lar iron homeostasis. Such proteins include divalentmetal transporter 1
(DMT1) and ferroportin 1 (FPN1), which have tightly relationship with
intracellular iron concentration. DMT1was known to be responsible for
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multiple transmembrane domain protein, which is the only cellular
iron efﬂux channel described so far [12]. Our previous studies showed
that upregulation of DMT1 with iron responsive element (IRE) and
downregulation of FPN1, accounted for intracellular iron excess in
6-OHDA induced PD models [13–16].
PD patients showed ampliﬁed levels of pro-inﬂammatory cyto-
kines in the SN as well as iron deposit. However, although effects of
pro-inﬂammatory cytokines on iron transport was investigated in
human monocytic cell lines [17,18], whether they were linked to do-
paminergic neuron iron accumulation was not clariﬁed. We supposed
that mis-regulation of iron transporters and iron accumulation in
dopaminergic neurons might be also attributable to the remarkably
increased cytokines by microglia. Therefore, the present study was
carried out to investigate the effects of pro-inﬂammatory cytokines
on iron transportation and expressions of iron transporters in prima-
ry cultured ventral mesencephalic (VM) neurons, as well as the
underlying mechanisms. To our knowledge, this is the ﬁrst report
demonstrating that pro-inﬂammation cytokines are associated with
the disturbance of neuronal iron homeostasis.
2. Materials and methods
2.1. Materials
All procedureswere carried out in accordancewith theNational Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals and the
Guidelines for the Use of Animals in Neuroscience Research. Recombi-
nant IL-1β, TNF-α, LPS, Greiss regent, ferric ammonium citrate (FAC),
FeSO4·7H2O, N-acetyl-L-cysteine (NAC), Nω-nitro-L-arginine methyl
ester hydrochloride (L-NAME), 1-methyl-4-phenylpyridinium (MPP+),
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and primary an-
tibody against tyrosine hydroxylase (TH) were from Sigma Chemical
Co. (St Louis, MO, USA). Primary antibodies against DMT1+IRE, FPN1
and iron regulatory protein 1 (IRP1) were from ADI (San Antonio, TX,
USA). Primary antibody against TfR1 was from Abcam (Cambridge, MA,
USA). Carboxy-H2DCFDA and calcein-AM were from Molecular Probes
(Molecular Probes Inc., Carlsbad, CA, USA). Dulbecco's modiﬁed Eagle's
medium (DMEM)/F12 and B27 were from Gibco (Grand Island, NY,
USA). All other chemicals and regentswere of the highest grade available
from local commercial sources.
2.2. Primary cell cultures
2.2.1. VM neuron culture
Primary cultures of mesencephalic neurons were obtained from em-
bryonic Sprague–Dawley rat mesencephalon as described previously
[19,20], with some modiﬁcations. Brieﬂy, regions of the ventral mesen-
cephalonwere dissected from embryonic 14-day rat brains and thenme-
chanically dissociated with a pipette, until the tissue is dispersed. After
centrifugation, cells were suspended in DMEM/F12 supplemented with
10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL
streptomycin and seeded at a density of 1×106cells/mL on poly-D-
lysine-coated coverslips or 12-well culture plates. Cells were grown in
a humidiﬁed atmosphere of 5% CO2 at 37 °C for 18 h, and then the cul-
ture medium was changed to serum free DMEM/F12 supplemented
with 2% B27. Cells were grown for a further 4 days before use. Neuron
purity was about 95% based on immunoﬂuorescence staining with a
speciﬁc neuron marker microtubule-associated protein 2 (MAP2).
Approximately 5% of the neurons exhibited TH positivity, which were
dopaminergic neurons.
2.2.2. Microglia culture
Primary microglia were isolated from newborn Sprague–Dawley rat
according to a previous study [21], with some modiﬁcations. Brieﬂy,
cerebral cortices were dissected from 1-day-old Sprague–Dawley rats,stripped of the meninges and mechanically dissociated with a pipette,
until it is dispersed. After centrifugation, cells were suspended in
DMEM/F12 supplemented with 10% fetal bovine serum (FBS),
100 U/mL penicillin, and 100 μg/mL streptomycin and seeded in poly-
D-lysine-coated 150 cm2 ﬂasks (5 brains/ﬂask). Cells were grown in a
humidiﬁed atmosphere of 5% CO2 at 37 °C. After 14 days, microglia
were harvested in culture media containing serum by shaking the ﬂasks
at 180 rpm for 1 h. After centrifugation, the cell suspension was plated
on 24-well plates at a density of 1×106cells/mL for further experiments
as described below. The purity of themicroglial cultureswas greater than
95% based on immunoﬂuorescence staining with a speciﬁc microglial
marker CD11b.
2.3. Calcein loading of cells and ferrous iron inﬂux and efﬂux assay
Ferrous iron inﬂux into neurons was determined by the quenching of
calcein ﬂuorescence as described before in our lab [13,22]. Neurons were
seeded to coverslips and grown in serum-free medium with 10 ng/mL
IL-1β or TNF-α for 24 h. Then, they were loaded with calcein-AM
(0.5 μmol/L ﬁnal concentration) in HEPES-buffered saline (HBS;
10 mmol/LHEPES, 150 mmol/LNaCl, pH 7.4) for 30 min at 37 °C. The ex-
cess calcein on the cell surface was washed out with HBS for 3 times, and
the coverslipsweremounted in a perfused chamber. Calceinﬂuorescence
was recorded at 488 nm excitation and 525 nm emission wavelengths,
and ﬂuorescence intensity was measured every 3 min for 7 times while
perfusing with 0.1 mmol/L ferrous iron (ferrous sulfate in ascorbic acid
solution, 1:44 molar ratio, pH 6.0, prepared immediately prior to the
experiments). Ascorbic acid maintained the reduced status of ferrous
iron; in addition, ascorbate acted as a chelator to maintain the iron in
solution. For iron efﬂux assay, neurons were perfused with 0.1 mmol/L
ferrous iron for 20 min, then ﬂuorescence intensity was measured
every 3 min for 7 times while perfusing with 1 mmol/L deferoxamine
(DFO), a membrane-impermeant, strong and speciﬁc iron chelator,
and the intracellular iron was drained out to the medium, indicated
by the increase in calcein ﬂuorescence [23,24]. The mean ﬂuorescence
signal of 25–30 single cells in four separate ﬁelds was monitored at
×200 magniﬁcation and processed with Fluoview 5.0 software.
2.4. Western blots
VMneuronswere seeded in 12-well plates and incubatedwith IL-1β
or TNF-α as described above. After 3 washes with cold PBS, cells were
lysed with lysis buffer containing 50 mmol/L Tris HCl, 150 mmol/L
NaCl, 1% Nonidet-40, 0.5% sodium deoxycholate, 1 mmol/L EDTA,
1 mmol/L phenylmethylsulfonyl ﬂuoride (PMSF), and protease inhibi-
tors (pepstatin 1 μg/mL, aprotinin 1 μg/mL, leupeptin 1 μg/mL) for
30 min on ice and the insolublematerialwas removedby centrifugation
(12,000 rpm, 20 min, 4 °C). The protein concentration was determined
by the Bradford assay kit (Bio-Rad Laboratories, Hercules, CA). A total of
sixty micrograms proteinwas separated using 10% SDS-polyacrylamide
gels and then transferred onto PVDF membranes. After overnight
blockingwith 10% non-fat milk at 4 °C, themembranes were incubated
with rabbit anti-rat DMT1+IRE (1:500) or IRP1 (1:500) antibody for
overnight at 4 °C, TfR1(1:1000) or FPN1 antibody (1:8000) for 1 h at
room temperature. Anti-rabbit secondary antibody conjugated to horse-
radish peroxidase was used at 1:0,000 (Santa Cruz Biotechnology, Santa
Cruz, CA). β-Actin was detected by mouse anti-β-actin monoclonal anti-
body (1:8000) according to a similar procedure to ensure equal samples
of protein. Cross-reactivity was visualized using ECL Western blotting
detection reagents and then analyzed through scanning densitometry
by a UVP BioDoc-It Imaging System (UVP, Upland, USA).
2.5. Total RNA extraction and quantitative PCR
Total RNA was isolated by using Trizol Reagent (Invitrogen) from
neurons treated as described above according to the manufacturer's
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reaction with oligo-dT primers using reverse-transcription system
(Promega). Quantitative RCR was employed to detect the changes
of hepcidin. TaqMan probe and the primers were designed to se-
quences using the default settings of Primer Express 2.0 (PE Applied
Biosystems).Primers was used with a TaqMan probe labeled at the
5′-end with the 6-carboxyﬂuorescein (FAM) reporter dye and at the
3′-end with the 6-carboxy-tetramethylrhodamine (TAMRA) quencher
dye. Hepcidin forward 5′-CTC CGG CAA CAG ACG AGA C-3′, reverse
5′-TTA CAG CAT TTA CAG CAG AAG AGG-3′, probe 5′-TGG TGT CTC
GCT TCC TTC GCT TCA G-3′. Rat GAPDH gene was used as the reference:
forward 5′-CCC CCA ATG TAT CCG TTG TG-3′, reverse 5′-GTA GCC CAG
GAT GCC CTT TAG T-3′, probe 5′-TCT GAC ATG CCG CCT GGA GAA
ACC-3′. Reactions were carried out in an Eppendorf Realplex4S System
using the relative quantiﬁcation option of the Mastercycler ep Realplex
2.2 software. Each reaction was run in triplicate with 2 μL sample in a
total volume of 20 μL with primers and probes to a ﬁnal concentration
of 0.25 μmol/L. A passive reference dye, ROX II, which was not
involved in ampliﬁcation,was used to correct forﬂuorescentﬂuctuations
resulting from changes in the reaction conditions for normalization of
the reporter signals. Ampliﬁcation and detection were performed with
the following conditions: an initial hold at 95 °C for 10 s followed by
40 cycles at 95 °C for 5 s and 60 °C for 45 s.
2.6. Nitrite assay
Levels of the nitric oxide (NO) derivative nitritewere detected in the
culture supernatants of VM neurons with the Griess reaction. After
treatment with IL-1β or TNF-α as described above, supernatants were
harvested and then mixed with equal volumes of 1× Greiss Reagent
(Sigma) in a 96-well plate. After incubation for 15 min at room temper-
ature, the mixtures were read with a microplate reader at 540 nm and
nitrite levels were extrapolated from a sodium nitrite standard curve.
2.7. Flow cytometric measurement of reactive oxygen species (ROS)
To evaluate the intracellular ROS generation during IL-1β or TNF-α
induced oxidative stress, VM neurons were incubated in HBS with
DCFH2-DA and then analyzed by ﬂow cytometry. The dye DCFH2-DA
can penetrate into cells and becomes hydrolyzed to non-ﬂuorescent
dichloroﬂuorescein (DCF). DCF then reactswith “ROS” to form the high-
ly ﬂuorescent dichloroﬂuorescein. The ﬂuorescence intensity reﬂects
the ROS generation inside cells [25]. After treatment with IL-1β or
TNF-α as described above. DCFH2-DA (5 μmol/L) was added and incu-
bated for 30 min at 37 °C after washing with HBS for 3 times. And
then neurons were re-suspended in 1 mL HBS. For analysis, excitation
and emission wavelengths 488 and 525 nm, respectively were used to
assess 10,000 cells from each sample. Results were demonstrated as
FL1-H (Fluorescence 1-Histogram), setting the gated region M1 and
M2 as a marker to observe the changing levels of ﬂuorescence intensity
using Cellquest Software.
2.8. Enzyme-linked immunoabsorbent assay (ELISA) of IL-1β and TNF-α
Microglia were cultured in 24-well plates, pre-incubated for 24 h
with 100 μmol/L FAC, and then stimulated for another 24 h with
800 ng/mL LPS or 100 μmol/L MPP+ [26]. Culture supernatants were
collected, and the concentrations of IL-1β and TNF-αwere determined
using ELISA kits (R&D Systems, Minneapolis, MN, USA) as described in
the manufacturers' instructions.
2.9. Animal models and double-immunoﬂuorescence labeling
for DMT1+IRE and TH
Eight to 10-week-old, male, C57BL/6 mice (Vital River Laboratory
Animal Technology, Beijing, China) were housed with free access tofood and water. The mice received a single intraperitoneal injection of
saline or salicylate (50 mg/kg) 5 min before a subcutaneous injection
of MPTP (30 mg/kg, 4 times a day) or saline, and 2 days after MPTP or
saline administration the mice were sacriﬁced. They were deeply anes-
thetized (8% chloral hydrate, i.p.) and transcardially perfused with nor-
mal saline and 4% paraformaldehyde in 0.1 mol/L PBS. Brain blocks
containing the SN were sectioned coronally at 20 μm on a freezing mi-
crotome (Leica). Sections were rinsed in PBS ﬁrst and then incubated
in 10% goat serum overnight at 4 °C to block non-speciﬁc binding,
followed by incubation overnight with primary antibodies consisting
of DMT1+IRE (1:100) along with TH (1:1000). The sections were
then washed 3 times with PBS, and incubated in the second antibody
consisting of Rhodamine-conjugated goat-anti-rabbit IgG (1:200) and
FITC-conjugated goat-anti-mouse IgG (1:200) for 2 h at room tempera-
ture. After mounting on the coverslips, sections were examined using a
Fluoview FV500 laser confocal scanning microscope (Olympus, Japan).
Control sections incubated in a solution without primary antibodies
showed no staining (data not shown).
2.10. Statistical analysis
Results are presented as means±S.E.M. Differences between
means in two groups were compared using the unpaired-samples t
test. One-way analysis of variance (ANOVA) followed by the Student–
Newman–Keuls test was used to compare difference between means
in more than two groups. Inﬂux and efﬂux studies were carried out
using two-way ANOVA followed by the Student–Newman–Keuls test;
data are presented as means±S.D. A probability of Pb0.05 was taken
to indicate statistical signiﬁcance.
3. Results
3.1. IL-1β or TNF-α increased ferrous iron inﬂux and decreased iron ef-
ﬂux of VM neurons
To elucidate whether IL-1β or TNF-α could affect intracellular iron
homeostasis bymodulating transmembrane transport,we usedﬂuores-
cence dye calcein to measure the ferrous iron uptake and outﬂow pro-
cess in VM neurons. After perfusing with 0.1 mmol/L ferrous iron, the
ﬂuorescence intensity signiﬁcantly decreased in IL-1β or TNF-α treated
neurons comparedwith the control (Fig. 1A), indicating that cells treat-
edwith IL-1β or TNF-α showed increased ferrous iron uptake. For efﬂux
experiments, the ﬂuorescence intensity reverse was analyzed when
neurons were perfused with 1 mmol/L DFO. The quenching was more
weakly reversed in IL-1β or TNF-α treated VM neurons compared
with the control (Fig. 1B), indicating a decrease iron efﬂux process in
these cells. The lower ﬂuorescence intensity conﬁrmed elevated iron
levels in IL-1β or TNF-α treated VM neurons. There was no difference
between IL-1β and TNF-α group in iron inﬂux and efﬂux process.
10 ng/mL IL-1β or TNF-α had no effects on cell viability of VM neurons,
indicating that the changes in iron inﬂux/efﬂux are not due to a change
in cell number.
3.2. IL-1β or TNF-α induced upregulation of IRP1 was responsible for
upregulation of TfR1 and DMT1+IRE, and downregulation of FPN1 in
VM neurons
To determine the reason for the modulation of iron transporta-
tion in IL-1β or TNF-α treated neurons, we investigated the expres-
sion of DMT1+IRE and FPN1 using Western blotting. DMT1+IRE
protein levels were signiﬁcantly increased; while FPN1 levels were
decreased compared with the control (Fig. 2).
Both DMT1+IRE and FPN1 have IRE in their mRNAs, we hypothe-
sized that IL-1β or TNF-α induced regulation of DMT1+IRE and FPN1
might be dependent on IRE/IRP system. Therefore, we examined the
expression of IRP1, an intracellular IRE-binding protein, in IL-1β or
Fig. 1. IL-1β or TNF-α enhanced ferrous iron inﬂux and attenuated iron efﬂux in VM
neurons. Ferrous iron inﬂux into VM neurons (A) was determined by the quenching
and iron efﬂux (B) was determined by the reverse quenching of calcein ﬂuorescence,
which is an indicator of intracellular iron level. The ﬂuorescence intensity represents
the mean value of 25–30 cells from four separate ﬁelds at each time point and is
presented as the mean±SD of six independent experiments. (A) Neurons treated
with 10 ng/mL IL-1β or TNF-α showed rapid and steady ﬂuorescence quenching
with ferrous iron perfusion. (B) The quenching was less reversed in IL-1β or TNF-α
treatment VM neurons with DFO perfusion (two-way ANOVA, Pb0.01, compared
with the control).
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1.53 fold and 1.32 fold, respectively (Fig. 5). These results indicated that
IRP1 upregulation might be responsible for IL-1β or TNF-α induced
upregulation of DMT1+IRE and downregulation of FPN1. TfR1, another
important IRP1 targeting protein in regulating intracellular iron homeo-
stasis, was also upregulated in IL-1β or TNF-α treated VM neurons
(Fig. 2).
Inﬂammation readily induced hepcidin expression by STAT3 signal-
ing pathway mediated by pro-inﬂammatory cytokines [27]. As the re-
ceptor for hepcidin, FPN1 could be internalized and degraded [28]. We
further analyzed hepcidin mRNA levels with real-time PCR. Hepcidin
mRNA was found increased to 2.691±0.657 or 3.320±1.235 folds,Fig. 2. IL-1β or TNF-α upregulated DMT1+IRE and TfR1 expressions and downregulated FP
FPN1 was downregulated when VM neurons were treated with 10 ng/mL IL-1β or TNF-α
presented as the ratio of DMT1+IRE or FPN1 to β-actin. Each bar represented the mean±respectively, in VM neurons treated with IL-1β or TNF-α. The result in-
dicated that in addition to IRP/IRE system, hepcidin participated in the
regulation of FPN1 expression in IL-1β and TNF-α treated VM neurons.
3.3. Oxidative stress and NO accounted for IL-1β or TNF-α induced IRP1
upregulation
Both oxidative stress and NO could activate IRP1 [29], therefore, we
surmised that upregulation of IRP1 might be initiated by intracellular
oxidative stress and/or NO induced by the pro-inﬂammatory cytokines.
To test this hypothesis, we ﬁrst quantiﬁed the changes of intracellular
ROS levels and the concentration of nitrite in cells supernatants in
IL-1β or TNF-α treated VM neurons. Increased levels of ROS and NO
were observed, and pretreatment with radical scavenger NAC or induc-
ible NO synthetase (iNOS) inhibitor L-NAME could fully abolish IL-1β or
TNF-α induced ROS or nitrite augment (Figs. 3, 4). Co-administration of
NAC and L-NAME could bring IRP1 expression returned to the basal
level in IL-1β or TNF-α treated VM neurons, however, sole treatment
with NAC or L-NAME just partially attenuated IL-1β or TNF-α induced
IRP1 upregulation (Fig. 5). This indicated that both ROS and NO were
responsible for IRP1 activation in these cells.
3.4. IL-1β and TNF-α levels were enhanced in activated microglia with
iron load
The above results indicated IL-1β or TNF-αmodulates iron homeo-
stasis in VM neurons. We next quantiﬁed IL-1β and TNF-α in microglia
culture supernatants to evaluate whether IL-1β and TNF-α released
might be affected under the condition of iron load. Primary microglia
were treated with 100 μmol/L FAC for 24 h, and then activated with
LPS (800 ng/mL) or MPP+ (100 μmol/L) for another 48 h. The condi-
tioned medium from the control or sole FAC treated microglia had
barely detectable levels of any of the cytokines examined. Activatedmi-
croglia by LPS showed a dramatic IL-1β and TNF-α secretion, however,
MPP+ insult exhibited relatively weaker effects. In the presence of iron,
these pro-inﬂammatory cytokine secretions induced by LPS or MPP+
were further enhanced (Fig. 6).
3.5. Salicylate application did not block DMT1+IRE upregulation in
dopaminergic neurons of the SN in MPTP-intoxicated mice
MPTP-intoxicated mice were used to implicate the role of microg-
lia (or pro-inﬂammatory cytokines) in causing iron accumulation inN1 expression in VM neurons. (A, B, C) DMT1+IRE and TfR1 were upregulated; while
for 24 h. β-actin was used as a loading control. (D, E, F) Statistical analysis. Data are
S.E.M. of six independent experiments. *Pb0.05, compared with the control.
Fig. 3. IL-1β or TNF-α increased ROS generation in VM neurons. (A) Representative ﬂuorometric assays of ROS generation in different groups. VM neurons treated with 10 ng/mL
IL-1β or TNF-α for 24 h increased ROS generation compared with the control; pretreatment with NAC fully abolished these effects. (B) Statistical analysis. Data are presented as
means±S.E.M. of six independent experiments. *Pb0.01, compared with the control; #Pb0.01, compared with IL-1β treated group; ^Pb0.01, compared with TNF-α treated group.
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inﬂammatory cytokines secretion [30–32], salicylate application could
protect dopaminergic neurons against MPTP neurotoxicity [33,34]. The
results showed that consistent in previous publication, 2 days after
MPTP intoxication, DMT1+IRE was upregulated in dopaminergic neu-
rons of the SN [35]. However, 50 mg/kg salicylate application did not
block this effect (Fig. 7).
4. Discussion
This study provides evidence that ﬁrst, TfR1 and DMT1+IRE were
upregulated and FPN1 was downregulated in IL-1β or TNF-α treated
VM neurons, which accounted for altered iron transportation and the
elevation of iron levels. Second, IL-1β or TNF-α aggravated hepcidin
production, ROS and NO generation in VM neurons, the latter then
resulted in activation of IRP1 and, led to mis-regulation of these iron
transporters. Finally, cellular iron homeostasis inﬂuenced the secretion
of IL-1β and TNF-α in activated microglia.
Microglia respond to activating stimuli in the extracellular envi-
ronment including endotoxin, chemokines, mis-folded proteins and
serum factors by releasing substantial pro-inﬂammatory cytokines
[36]. IL-1β and TNF-α is major component of neuro-inﬂammation
which plays a key role in PD. Increased levels of IL-1β and TNF-α
have been detected in the cerebrospinal ﬂuid, as well as postmortemFig. 4. IL-1β or TNF-α increased nitrite generation in VM neurons conditioned medium.
VM neurons treated with IL-1β or TNF-α for 24 h increased nitrite generation
compared with the control; pretreatment with L-NAME fully abolished these effects.
Data are presented as means±S.E.M. of six independent experiments. *Pb0.01, com-
pared with control; #Pb0.01, compared with IL-1β treated group; ^Pb0.01, compared
with TNF-α treated group.brains (e.g. SN and striatum) of PD patients [1]. Elevation of IL-1β and
TNF-αwas linked to dopaminergic neuron loss in both animal models
and cultured cells [37]. However, currently, how IL-1β and TNF-αFig. 5. Inhibition of ROS and NO blocked IRP1 activation in IL-1β or TNF-α treated VM
neurons. (A, B) The expression of IRP1 signiﬁcantly increased in VM neurons treated
with IL-1β or TNF-α. These effects were partially attenuated by pretreatment with
either NAC or L-NAME, however, fully abolished in cells pretreatment with both NAC
and L-NAME. β-actin was used as a loading control. (C, D) Statistical analysis. Data
are presented as the ratio of IRP1 to β-actin. Each bar represented the mean±S.E.M.
of six independent experiments. *Pb0.05, compared with the control, respectively;
#Pb0.05, compared with IL-1β; ^Pb0.05, compared with TNF-α.
Fig. 6. FAC enhanced IL-1β and TNF-α release from activated microglia triggered by LPS
or MPP+. FAC alone did not increase the release of cytokines. Activation of microglia
with LPS or MPP+ increased both IL-1β and TNF-α release, and this was further
enhanced by initial FAC incubation. *Pb0.01, compared with the control; #Pb0.05,
compared with LPS; ^Pb0.05, compared with MPP+.
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our experiments, we found that IL-1β or TNF-α increased ferrous iron
inﬂux and decreased iron efﬂux, thus leading to iron overload in VMFig. 7. DMT1+IRE expression in the SN of MPTP-intoxicated mice. There was a modest ex
mice (top). DMT1+IRE expression was upregulation in the SN 2 days after MPTP intoxica
TH-positive neurons (bottom).neurons. This might be linked to activated microglia and neuron in-
teractions in PD pathogenesis, among which iron accumulation in neu-
rons plays a key role [38]. Although suppression of pro-inﬂammatory
cytokines secretion by salicylate did not block DMT1 upregulation in do-
paminergic neurons of the SN in MPTP-intoxicated mice, together with
the in vitro data that IL-1β or TNF-α modulated iron transportation in
neurons, we supposed that these pro-inﬂammatory cytokines might
not be themain contributor, however, aggravate the nigral iron accumu-
lation in PD in vivo.
Upregulation of DMT1 and downregulation of FPN1were separately
accounted for enhanced ferrous iron inﬂux and attenuated iron efﬂux in
neuronal cells [15,24]. In the present study, we observed that the ex-
pression of DMT1 increased and FPN1 decreased, and what's more,
the level of IRP1 was elevated in IL-1β or TNF-α treated neurons. IRPs
could respond to cellular iron status and coordinate the iron homeosta-
sis by binding to IRE. According to IRE–IRP theory, upregulated IRP1
binding to IRE increased DMT1 mRNA stability and repressed FPN1
mRNA translation. This is further conﬁrmed by the result that another
important IRP1 targeting protein with IRE, TfR1, was also upregulated
in IL-1β or TNF-α treated VM neurons. These results were consistent
with our studies as well as other groups indicating that IRP1 regulates
the expression levels of DMT1 and FPN1, and further conﬁrmed by the
fact and IRP1 knockdown induced a contrary regulation on these two
transporters [13,39]. Furthermore, pro-inﬂammatory cytokines that in-
duced hepcidin upregulation might have participated in the regulation
of FPN1 expression in IL-1β and TNF-α treated neurons.
IRPs could sense intracellular iron status and participate in the
maintenance of cellular iron homeostasis. Much more abundant than
IRP2 in most cells and tissues, usually IRP1 made a greater contributionpression of DMT1+IRE (green) in TH (red)-positive dopaminergic neurons in control
tion (middle), and salicylate application had no effects on DMT1+IRE expression in
624 J. Wang et al. / Biochimica et Biophysica Acta 1832 (2013) 618–625to IRE-binding activity than IRP2, thus bond with higher afﬁnity to the
DMT1+IRE [40,41]. Oxidative stress also preferentially inﬂuences IRP1
because of the presence of the Fe–S cluster in IRP1 [42]. Therefore, we
mainly focused on IRP1 in our studies. IRP1 has two mutually exclusive
activities, which either bind an IRE site or function as a cytosolic isoform
of aconitase [43]. In iron-deﬁcient cells, IRP1 binds with high afﬁnity to
IRE.Whereas in iron-replete cells, a 4Fe–4S cluster in IRP1 is fully assem-
bled, and endowedwith aconitase activity [44]. In addition to iron, reac-
tive oxygen species and NO may activate IRP1 through disassembling
the 4Fe-4S cluster, leading to the loss of cytoplasmic aconitase activity
and the acquisition of high-afﬁnity RNA binding capacity, thus confer
IRP1's function as a posttranscriptional regulator [29]. As shown in our
experiment, IL-1β or TNF-α generated substantial NO and ROS, thus in-
ducing activation of IRP1 in neurons. Both ROS and NO could enhanced
hypoxia-inducible factor HIF-1α activation [45–47], the latter then af-
fects iron homeostasis by modulating several iron transporters, for ex-
ample upregulating TfR1 [48]. However, recently it was reported that
HIF could mediate IRP1 downregulation, as a dual-luciferase reporter
assay provides direct evidence that HIF/HRE system was an essential
link between IRP1 and HIF interactions [49]. We observed IRP1
upregulation in pro-inﬂammatory cytokines treated VM neurons,
suggesting HIF might not be involved in this process. Actually, IRP1
acts as the dominant sensor and transducer of NO, as it stimulates
the IRE-binding activity of IRP1 by targeting its Fe–S cluster [50].
IRP1 returned to basal level by pretreatment with iNOS inhibitor
L-NAME and radical scavenger NAC together, however, either inhib-
itor alone just partially abolished IRP1 overexpression. Taken to-
gether, our results suggest that ROS and NO generated by IL-1β or
TNF-α induced activation of IRP1, leading to mis-regulation of iron
transporters in VM neurons.
As demonstrated above, IL-1β or TNF-α could modulate iron trans-
port and resulted in iron accumulation in VM neurons. In vivo, iron
load occurred inmicroglia in PD,whichmight be derived fromdamaged
neurons. Endotoxin LPS wasmost commonly used to activate microglia
both in vivo and in vitro [51]. By binding to toll-like receptor (TLR) 4,
LPS initiates activation of NF-κB that results in production of pro-
inﬂammatory cytokines such as IL-1β and TNF-α [52]. We supposed
that iron could aggravate ROS generation,whichpromoted inﬂammato-
ry signals leading to activation of NF-κB and the consequent raising
cytokine contents [53]. In the present study, we further revealed
that the elevation of iron levels in activated microglia triggered by
LPS or MPP+ induced more IL-1β and TNF-α release. With this vicious
cycle, activated microglia exacerbates neuronal iron accumulation and
consequent degeneration in PD.
In summary, this study provides novel insight into unraveling that
microglia might aggravate iron mediated neuropathologies by secreting
IL-1β and TNF-α in PD. Oxidative stress and NO induced by IL-1β or
TNF-α activated IRP1, regulated expression of TfR1, DMT1+IRE and
FPN1, thus leading to neuronal iron accumulation and even demise.
This process was enhanced when microglia were iron-loaded. We sup-
posed this might be extremely deleterious when microglia activation
and iron deposit simultaneously occurred in PD. Epidemiological studies
reported that chronic administration of aspirin or other NSAIDs decrease
the risk of developing PD [54]. Our experiments provide powerful
evidence that anti-inﬂammation and iron chelation could protect dopa-
minergic neurons by maintaining neuronal iron homeostasis, and show
lights on the co-administration of anti-inﬂammatory agents and iron
chelators could be a valuable therapeutic approach in PD.
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